文献速递糖尿病肥胖与代谢综合征垂体与肾上腺疾病

小于胎龄儿接受生长激素治疗后的糖胰岛素代谢与肥胖儿童相似

Children born SGA receiving growth hormone have similarly impaired glucose-insulin metabolism as children with obesity.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本研究比较了接受生长激素治疗的小于胎龄儿(SGA)与特发性生长激素缺乏症(iGHD)、肥胖及瘦对照组儿童的糖胰岛素代谢。结果显示,未治疗的SGA-GHT患者胰岛素抵抗高于iGHD患者,接近肥胖儿童水平;GH治疗期间SGA-GHT的HbA1c高于瘦对照组,糖尿病前期患病率最高(11.11%)。停用GH后SGA-GHT仍保持较高的糖尿病前期和胰岛素抵抗标志物,建议密切代谢监测。

要点

  • SGA-GHT患者胰岛素抵抗程度接近肥胖儿童。
  • GH治疗期间SGA-GHT的糖尿病前期患病率最高(11.11%)。
  • 停用GH后SGA-GHT仍存在代谢异常,需密切监测。

核心结论

  • SGA患者存在与肥胖儿童相似的糖胰岛素代谢受损,GH治疗会使其进一步恶化,建议密切代谢监测。

研究设计与样本

  • 研究分析了134例未追赶生长的SGA-GHT患者、27例未治疗的SGA-CUG患者、308例接受GH治疗的iGHD患者、427例肥胖儿童和356例瘦对照者的口服葡萄糖耐量试验指数和空腹参数。
  • 通过匹配和多变量回归对性别、年龄和BMI进行了调整。

主要发现

  • GH治疗下,SGA-GHT和iGHD患者的HbA1c(5.26%±0.35 vs 5.25%±0.25)高于瘦对照组(5.09%±0.27)。
  • SGA-GHT患者的糖尿病前期患病率最高(11.11%),高于iGHD(1.59%)和肥胖(3.13%)。
  • 停用GH后,SGA-GHT患者仍保持较高的糖尿病前期(4.65%)和胰岛素抵抗标志物,与肥胖儿童(6.38%)相似。
  • 未观察到明显的2型糖尿病。

临床怎么用

  • 对接受GH治疗的SGA患者应进行密切的代谢监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Being born small for gestational age (SGA) and growth hormone (GH) treatment are linked to disturbed glucose-insulin metabolism. OBJECTIVE: We investigated how GH treatment affects glucose-insulin metabolism in children born SGA compared to children with isolated growth hormone deficiency (iGHD), obesity and lean controls. METHODS: We analyzed glucose-insulin metabolism indices derived from oral glucose tolerance tests (Matsuda index, AUC insulin) and fasting parameters (fasting glucose, HOMA-IR) in 134 SGA patients without catch-up growth (CUG) receiving GH therapy (SGA-GHT), 27 untreated SGA patients with catch-up growth (SGA-CUG), 308 iGHD patients under GH treatment, 427 children with obesity, and 356 lean controls. We adjusted for sex, age, and BMI through matching and multivariable regression. RESULTS: Treatment-naïve SGA-GHT patients were more insulin-resistant than iGHD patients (higher insulin AUC [P = .002] and HOMA-IR [P < .001], lower Matsuda index [P < .001]) with levels approaching those of the obesity cohort. Under GH therapy, HbA1c was higher in SGA-GHT and iGHD patients (5.26% ± 0.35 vs 5.25% ± 0.25) than in lean controls (5.09% ± 0.27). Insulin resistance in SGA-GHT patients approached levels seen in obesity. Prediabetes prevalence was highest in SGA-GHT children (11.11%) compared to those with iGHD (1.59%) or obesity (3.13%). After stopping GH therapy, SGA-GHT patients retained elevated markers of prediabetes (4.65%) and insulin resistance compared to controls and iGHD patients, similar to children with obesity (6.38%). No overt type 2 diabetes was observed. CONCLUSION: SGA patients have an impaired glucose-insulin metabolism similar to that of children with obesity, which worsens under GH therapy. Close metabolic monitoring of GH-treated SGA patients is recommended.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Prengemann L, Stein R, Gausche R, et al. Children born SGA receiving growth hormone have similarly impaired glucose-insulin metabolism as children with obesity. J Clin Endocrinol Metab. 2026. PMID: 41665939. doi:10.1210/clinem/dgaf672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。